Apollo Hospitals Enterprise (BOM:508869) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


BOM:508869 Apollo Hospitals Enterprise Ltd BOM:508869
92 GF Score
Price ₹8,897.35
GF Value ₹8,723.27
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Apollo Hospitals Enterprise Research & Development?

Apollo Hospitals Enterprise BOM:508869 +2.30% 92 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates BOM:508869 with a GF Score™ of 92/100 and a GF Value™ of ₹8,723.27 (Fairly Valued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Apollo Hospitals Enterprise's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Apollo Hospitals Enterprise  (BOM:508869) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Apollo Hospitals Enterprise Research & Development Related Terms

Apollo Hospitals Enterprise Research & Development Historical Data

* Premium members only.

The historical data trend for Apollo Hospitals Enterprise's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollo Hospitals Enterprise Research & Development Chart

Apollo Hospitals Enterprise Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Apollo Hospitals Enterprise Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:508869
92GF Score
Apollo Hospitals Enterprise Ltd BOM:508869
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apollo Hospitals Enterprise Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Apollo Hospitals Enterprise (BOM:508869) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Apollo Hospitals Enterprise and its competitors.
Is Apollo Hospitals Enterprise's Research & Development too high?
Apollo Hospitals Enterprise's current Research & Development is ₹0 Mil. Overall, Apollo Hospitals Enterprise has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apollo Hospitals Enterprise's Research & Development compare to HCA and THC?
Apollo Hospitals Enterprise's Research & Development of ₹0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Apollo Hospitals Enterprise and its competitors. Apollo Hospitals Enterprise's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollo Hospitals Enterprise stock overvalued right now?
Based on GuruFocus' analysis, Apollo Hospitals Enterprise (BOM:508869) is currently considered Fairly Valued. The stock's GF Value™ is ₹8,723.27, compared to a current price of ₹8,897.35 — trading 2% above its estimated fair value. The current Research & Development is ₹0 Mil. Apollo Hospitals Enterprise's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Apollo Hospitals Enterprise (BOM:508869), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apollo Hospitals Enterprise (BOM:508869) Overvalued in 2026?

Based on GuruFocus' analysis, Apollo Hospitals Enterprise stock appears to be overvalued. The current stock price of ₹8,897.35 is trading 2% above its estimated GF Value™ of ₹8,723.27. GuruFocus considers Apollo Hospitals Enterprise to be Fairly Valued.

Key valuation signals for BOM:508869:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹8,723.27 vs. price of ₹8,897.35 (2% above fair value)
  • GF Score™: 92/100 with 4 warning signs

No single metric tells the full story. See the BOM:508869 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Apollo Hospitals Enterprise Business Description

Other Exchanges APOLLOHOSP:India
Address No. 8-17, Shafee Mohammed Road, Sunny Side Building, East Block, 3rd Floor, Chennai, TN, IND, 600006
Apollo Hospitals Enterprise Ltd operates a network of private hospitals in India through primary, secondary, and tertiary care facilities. The firm's tertiary care hospitals provide complex care in a variety of specialties that include cardiology, oncology, neuroscience, orthopedics, radiology, and gastroenterology. Apollo Hospitals also operates primary care and diagnostics clinics as well as telemedicine units and offers consulting, health insurance, education and training, and research services. Its reportable operating segments are; Healthcare Services (represents hospitals and hospitals services); Retail Health and Diagnostics (includes clinics and diagnostics); Digital Health and Pharmacy Distribution; and Others. Maximum revenue is generated from its Healthcare Services segment.
92GF Score

Get the complete analysis for BOM:508869

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹8,897.35
Price
₹8,723.27
GF Value